A low molecular weight synthetic inducer of interferon that stimulates the formation of alpha, beta, gamma interferons in the body. The main structures producing interferon in response to the introduction of tilorone are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After taking the drug inside, the maximum production of interferon is determined in the sequence of the intestine-liver-blood after 4-24 hours. Amiksin has an immunomodulating and antiviral effect.
In human leukocytes, induces the synthesis of interferon. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. Effective in various viral infections (including those caused by influenza viruses, other pathogens of acute respiratory viral infections, hepatitis viruses, herpes viruses). The antiviral mechanism of action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed
for the prevention and treatment of influenza and SARS;
for the treatment of viral hepatitis A, B and C;
for the treatment of herpes infection;
for the treatment of cytomegalovirus infection;
in the complex therapy of allergic and viral encephalomyelitis (including multiple sclerosis, leukoencephalitis, uveoencephalitis);
as part of complex therapy of urogenital and respiratory chlamydia;
as part of the complex therapy of pulmonary tuberculosis.
In children older than 7 years
for the treatment of influenza and SARS